The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease.

inflammatory bowel disease outcomes research symptom score or index

Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
22 Dec 2023
Historique:
received: 13 09 2023
medline: 22 12 2023
pubmed: 22 12 2023
entrez: 22 12 2023
Statut: aheadofprint

Résumé

The disease severity index (DSI) for inflammatory bowel disease (IBD) combines measures of disease phenotype, inflammatory activity, and patient-reported outcomes. We aimed to validate the DSI and assess its utility in predicting a complicated IBD course. A multicenter cohort of adults with IBD was recruited. Intraclass correlation coefficients (ICCs) and weighted Kappa assessed inter-rater reliability. Cronbach's alpha measured internal consistency of DSI items. Spearman's rank correlations compared the DSI with endoscopic indices, symptom indices, quality of life, and disability. A subgroup was followed for 24 months to assess for a complicated IBD course. Area under the receiver operating characteristics curve (AUROC) and multivariable logistic regression assessed the utility of the DSI in predicting disease progression. Three hundred and sixty-nine participants were included (Crohn's disease [CD], n = 230; female, n = 194; mean age, 46 years [SD, 15]; median disease duration, 11 years [interquartile range, 5-21]), of which 171 (CD, n = 99; ulcerative colitis [UC], n = 72) were followed prospectively. The DSI showed inter-rater reliability for CD (ICC 0.93, n = 65) and UC (ICC 0.97, n = 33). The DSI items demonstrated inter-rater agreement (Kappa > 0.4) and internal consistency (CD, α > 0.59; UC, α > 0.75). The DSI was significantly associated with endoscopic activity (CDn=141, r = 0.65, P < .001; UCn=105, r = 0.80, P < .001), symptoms (CDn=159, r = 0.69, P < .001; UCn=132, r = 0.58, P < .001), quality of life (CDn=198, r = -0.59, P < .001; UCn=128, r = -0.68, P < .001), and disability (CDn=83, r = -0.67, P < .001; UCn=52, r = -0.74, P < .001). A DSI of 23 best predicted a complicated IBD course (AUROC = 0.82, P < .001) and was associated with this end point on multivariable analyses (aOR, 9.20; 95% confidence interval, 3.32-25.49). The DSI reliably encapsulates factors contributing to disease severity and accurately prognosticates the longitudinal IBD course. This study shows that the disease severity index (DSI) for inflammatory bowel disease (IBD) is a valid and reliable instrument encapsulating the disease phenotype, disease activity, and impact of the disease on the patient; and it accurately predicts for incident disease complications.

Sections du résumé

BACKGROUND BACKGROUND
The disease severity index (DSI) for inflammatory bowel disease (IBD) combines measures of disease phenotype, inflammatory activity, and patient-reported outcomes. We aimed to validate the DSI and assess its utility in predicting a complicated IBD course.
METHODS METHODS
A multicenter cohort of adults with IBD was recruited. Intraclass correlation coefficients (ICCs) and weighted Kappa assessed inter-rater reliability. Cronbach's alpha measured internal consistency of DSI items. Spearman's rank correlations compared the DSI with endoscopic indices, symptom indices, quality of life, and disability. A subgroup was followed for 24 months to assess for a complicated IBD course. Area under the receiver operating characteristics curve (AUROC) and multivariable logistic regression assessed the utility of the DSI in predicting disease progression.
RESULTS RESULTS
Three hundred and sixty-nine participants were included (Crohn's disease [CD], n = 230; female, n = 194; mean age, 46 years [SD, 15]; median disease duration, 11 years [interquartile range, 5-21]), of which 171 (CD, n = 99; ulcerative colitis [UC], n = 72) were followed prospectively. The DSI showed inter-rater reliability for CD (ICC 0.93, n = 65) and UC (ICC 0.97, n = 33). The DSI items demonstrated inter-rater agreement (Kappa > 0.4) and internal consistency (CD, α > 0.59; UC, α > 0.75). The DSI was significantly associated with endoscopic activity (CDn=141, r = 0.65, P < .001; UCn=105, r = 0.80, P < .001), symptoms (CDn=159, r = 0.69, P < .001; UCn=132, r = 0.58, P < .001), quality of life (CDn=198, r = -0.59, P < .001; UCn=128, r = -0.68, P < .001), and disability (CDn=83, r = -0.67, P < .001; UCn=52, r = -0.74, P < .001). A DSI of 23 best predicted a complicated IBD course (AUROC = 0.82, P < .001) and was associated with this end point on multivariable analyses (aOR, 9.20; 95% confidence interval, 3.32-25.49).
CONCLUSIONS CONCLUSIONS
The DSI reliably encapsulates factors contributing to disease severity and accurately prognosticates the longitudinal IBD course.
This study shows that the disease severity index (DSI) for inflammatory bowel disease (IBD) is a valid and reliable instrument encapsulating the disease phenotype, disease activity, and impact of the disease on the patient; and it accurately predicts for incident disease complications.

Autres résumés

Type: plain-language-summary (eng)
This study shows that the disease severity index (DSI) for inflammatory bowel disease (IBD) is a valid and reliable instrument encapsulating the disease phenotype, disease activity, and impact of the disease on the patient; and it accurately predicts for incident disease complications.

Identifiants

pubmed: 38134391
pii: 7491613
doi: 10.1093/ibd/izad294
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Auteurs

Akhilesh Swaminathan (A)

Department of Medicine, University of Otago, Christchurch, New Zealand.
Department of Gastroenterology, Christchurch Hospital, New Zealand.

James M Fulforth (JM)

Department of Gastroenterology, Waikato Hospital, Hamilton, New Zealand.

Chris M Frampton (CM)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Grace M Borichevsky (GM)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Thomas C Mules (TC)

Department of Medicine, University of Otago, Christchurch, New Zealand.
Department of Gastroenterology, Christchurch Hospital, New Zealand.

Kate Kilpatrick (K)

Department of Gastroenterology, Christchurch Hospital, New Zealand.

Myriam Choukour (M)

Centre Hospitalier Régional Universitaire (CHRU) Nancy, Délégation à la Recherche Clinique et à l'Innovation, Plateforme Maladies Inflammatoires Chroniques de l'Intestin (MICI), Vandoeuvre-lès-Nancy, France.

Peter Fields (P)

Division of Gastroenterology and Hepatology, School of Medicine & Dentistry, University of Rochester, Rochester, NY, USA.

Resham Ramkissoon (R)

Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Emily Helms (E)

Department of Gastroenterology, Concord Hospital, Sydney, Australia.

Stephen B Hanauer (SB)

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Rupert W Leong (RW)

Department of Gastroenterology, Concord Hospital, Sydney, Australia.

Laurent Peyrin-Biroulet (L)

Deartment of Gastroenterology, Nancy University Hospital, F-54500 Vandoeuvre-les-Nancy, France.
INSERM, NGERE, University of Lorraine, F-54000 Nancy, France.
INFINY Institute, Nancy University Hospital, F-54500 Vandoeuvre-les-Nancy, France.
FHU-CURE, Nancy University Hospital, F-54500 Vandoeuvre-les-Nancy, France.
Groupe Hospitalier privé Ambroise Paré-Hartmann, Paris IBD Center, 92200 Neuilly sur Seine, France.
Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada.

Corey A Siegel (CA)

Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, LebanonNew Hampshire, USA.

Richard B Gearry (RB)

Department of Medicine, University of Otago, Christchurch, New Zealand.
Department of Gastroenterology, Christchurch Hospital, New Zealand.

Classifications MeSH